Iobenguane
- Generic Name
- Iobenguane
- Brand Names
- Azedra
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10IN3
- CAS Number
- 80663-95-2
- Unique Ingredient Identifier
- 35MRW7B4AD
- Background
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
- Indication
Detection of primary and metastatic pheochromocytoma or neuroblastoma
- Associated Conditions
- Metastatic Adrenal Gland Pheochromocytoma, Metastatic Neuroblastoma, Primary Neuroblastomas, Primary Pheochromocytomas, Unresectable, locally advanced iobenguane-scan positive Paraganglioma, Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas, Unresectable, metastatic iobenguane-scan positive Paraganglioma, Unresectable, metastatic iobenguane-scan positive Pheochromocytomas
- Associated Therapies
- -
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
Early Phase 1
Completed
- Conditions
- Neuroendocrine Tumors
- Interventions
- Drug: 3-[18F]Fluoro-para-hydroxyphenethylguanidineDiagnostic Test: Positron emission tomography/computed tomography scanDrug: [123I] metaiodobenzylguanidineDiagnostic Test: Planar scintigraphy scanDiagnostic Test: Single photon emission computed tomography/computed tomography scan
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT04510311
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- First Posted Date
- 2005-04-06
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT00107289
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath